Anika Reports Fourth Quarter and Full Year 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. GOOGL
9. RTX
10. COF

Go back to Anika Reports Fourth Quarter and Full Year 2018 Financial Results

Sidoti Downgrades Anika Therapeutics (ANIK) to Neutral

February 22, 2019 8:48 AM EST

Sidoti analyst James Sidoti downgraded Anika Therapeutics (NASDAQ: ANIK) from Buy to Neutral with a price target of $41.00 (from $56.00).

The analyst cited uncertainty regarding CINGAL approval.

For an analyst ratings summary and ratings history on Anika Therapeutics... More

Anika Therapeutics (ANIK) Tops Q4 EPS by 21c

February 21, 2019 4:20 PM EST

Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.54, $0.21 better than the analyst estimate of $0.33. Revenue for the quarter came in at $27 million versus the consensus estimate of $26.17 million.

Anika continued to deliver strong earnings and cash flow in the fourth quarter, entering 2019 well-positioned to... More